The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Ironwood Pharmaceuticals, Inc.
Zacks Investment Research on MSN
IRWD's Linzess wins FDA nod for expanded pediatric constipation use
Ironwood Pharmaceuticals IRWD announced that the FDA has approved the expanded use of its sole marketed drug, Linzess ...
Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...
Ironwood Pharmaceuticals IRWD announced that the FDA has accepted and granted priority review to a supplemental new drug application (sNDA), seeking expanded use of Linzess (linaclotide) for children ...
The updated label now states that the treatment is contraindicated in patients less than 2 years of age due to the risk of serious dehydration. The Food and Drug Administration has approved revised ...
The FDA expanded its approval of linaclotide to include pediatric patients aged 2 to 5 years with functional constipation.Linaclotide (Linzess, Ironwood Pharmaceuticals) received FDA approval in ...
Tablets explicitly designed for weight reduction might be an excellent choice for those who want to get rid of excess weight in a hurry without having to make significant changes to their eating ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for ...
– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pediatric patients 6 years of age and older – – LINZESS remains the first-and-only FDA-approved ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results